<DOC>
	<DOCNO>NCT03056664</DOCNO>
	<brief_summary>Here investigator carry phase II clinical trial explore effective therapeutic regimen MSC Crohn 's perianal fistula .</brief_summary>
	<brief_title>The Role MSC Treatment Fistulas Patients With Perianal Crohn 's Disease</brief_title>
	<detailed_description>Peri-anal fistula common see Crohn 's disease . Treatments include surgery , antibiotic , immunosuppressive drug infliximab improve quality life patient suffer Crohn 's perianal fistula , recurrent rate still high . MSC show promising effect therapy CD , standard treatment strategy unclear . Here investigator carry phase II clinical trial explore effective therapeutic regimen MSC Crohn 's perianal fistula .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<criteria>1 . Age 1865 year old , male female ; 2. refractory CD fistula , 12 13 mouth fistula ; 3 . Diagnostic CD least three month ; 4 . CDAI &lt; 250 ; 5. receive drug treatment ( 5ASA hormone &gt; 4 week , immunosuppressant biological agent &gt; 8 week ) ; 6. sign inform consent . 1. intestinal obstruction , stenosis , perianal abscess ; 2. pregnant lactate woman ; 3. infection need antibiotics person ; 4. rectovaginal fistula ; 5. complex anal fistula two inside mouth ; 6. stenosis perforation CD ; 7. perianal infection ; 8. could rectal anal stenosis local injection therapy ; 9. acute enteritis ; 10. , liver kidney dysfunction ; 11. month use drug clinical trial ; 12. condition unwilling carry MRI inspect ; 13. adjusting therapy ; 14 . HIV patient ; 15 . The combined active hepatitis tuberculosis ; Occurred 16 ) 6 month opportunistic infection , severe infection occur within three month ; 17 ) In past five year , suffer cancer ; 18 ) history lymphoproliferative disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>